ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

QNCX Quince Therapeutics Inc

0.9851
0.0251 (2.61%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Quince Therapeutics Inc QNCX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0251 2.61% 0.9851 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.92 0.92 0.99 0.9851 0.96
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/4/202406:00BWQuince Therapeutics Provides Business Update and Reports..
22/2/202406:00BWQuince Therapeutics Launches Scientific Advisory Board
15/2/202415:00EDGAR2Form 8-K - Current report
15/2/202406:00BWQuince Therapeutics Appoints Former Reata Pharmaceuticals..
07/2/202415:05BWQuince Therapeutics to Present at Oppenheimer 34th Annual..
02/2/202416:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:01EDGAR2Form 8-K/A - Current report: [Amend]
04/1/202415:05BWQuince Therapeutics to Participate at Investor Events in..
03/1/202415:02EDGAR2Form 8-K - Current report
22/12/202315:08EDGAR2Form 8-K - Current report
14/12/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202315:06EDGAR2Form 8-K - Current report
07/12/202317:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202312:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202316:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202318:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202318:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/10/202315:05EDGAR2Form 8-K - Current report
23/10/202306:00BWQuince Therapeutics Completes Acquisition of EryDel S.p.A.
28/9/202315:53DJNQuince Therapeutics to Advance Study of EryDex as FDA Lifts..
28/9/202315:05BWU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s..
06/9/202306:18EDGAR2Form 8-K - Current report
06/9/202306:00BWQuince Therapeutics Appoints Dr. Charles S. Ryan as..
31/8/202317:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202317:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202316:05EDGAR2Form 8-K - Current report
10/8/202315:05BWQuince Therapeutics to Present at Sidoti Virtual Investor..
09/8/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202317:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202315:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202316:56BWQuince Therapeutics rileva EryDel SpA e il suo asset di fase..
24/7/202306:16EDGAR2Form 8-K - Current report
24/7/202306:00BWQuince Therapeutics to Acquire EryDel SpA and its Phase 3..

Su Consulta Reciente

Delayed Upgrade Clock